Hi David,
Your contribution here is greatly appreciated. I have no doubt that the FAST1 is a great product. But as a shareholder, my biggest concern is time to market, partly because the affects my share value and also partly because I've seen products in other industries lose out to an inferior competitor because they were late to market.
Most of the companies I invest in are established technology firms where I can gauge their performance based on quarterly and annual returns vs. the projections of management and their guidance to analysts. Pyng is a little different since its main product isn't producing significant revenue. So the only way I can gauge performance is vs. execution to schedule. Based on Pyng's press releases and Micheal Jacobs postings here, I've made some overly optimistic estimates regarding that schedule. (Based on recent postings, it looks like some other people did the same). So now I'd like to have a realistic, perhaps even conservative schedule estimate for the completion of field trials, time to make modifications (after the number of trials already completed you must have a pretty good idea about what features if any need to be revised), and finally time to ramp to volume production (assuming orders follow the field trials).
Obviously there are some schedule details that you can't or may not wish to predict (when the US military reports will be released, when the first orders will come in, etc.) but I believe the data I have requested lies in the realm of data under Pyng's control or for which a simple linear interpolation can provide a reasonable estimate.
Armed with this information, we can make intelligent decisions about our current and potential future investments in Pyng, we can also then gauge the companies performance to some objective data, something which has been very difficult to do so far.
Warmest regards,
Barry Moss |
